Devyn joined Pfizer's Neusentis Research Unit in Sept. 2011 as Chief Operating Officer responsible for strategy and operations for the unit and in working with the Neusentis Leadership Team in implementing key strategies. Neusentis is a biotech-like unit within Pfizer R&D focused on pain and sensory disorders, and regenerative medicine. He joined Pfizer's Strategic Management Group in August 2009 supporting the head of Pharmatherapeutics R&D on developing and implementing business strategies and operational plans. Devyn speaks widely about Regenerative Medicine, particularly as it relates to commercialization challenges. He serves on the Alliance for Regenerative Medicine’s Executive Committee and as the Chair of the Commercialization Review Committee for the Canadian Centre for Commercialization of Regenerative Medicine.
Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies.
Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University. He is currently an adjunct faculty member at Northeastern University.